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OBJECTIVES We examined the association between glycemic control determined by preprocedural
hemoglobin A1c (A1c) and the incidence of target vessel revascularization (TVR) in diabetic
patients undergoing elective percutaneous coronary intervention (PCI).
BACKGROUND Patients with diabetes mellitus (DM) have increased rates of restenosis and a worse clinical
outcome after PCI than patients without DM.
METHODS A total of 239 patients (60 without DM and 179 with DM) were enrolled in this study.
Optimal glycemic control was defined as A1c 7%, and suboptimal control was defined as
A1c 7%. Follow-up was performed at six and 12 months after the index intervention.
RESULTS Diabetic patients with optimal glycemic control had a rate of 12-month TVR similar to that
of nondiabetic patients (15% vs. 18%, p  NS). Diabetic patients with A1c 7% had a
significantly higher rate of TVR than those with A1c 7% (34% vs. 15%, p  0.02). In a
multiple logistic regression analysis, A1c 7% was a significant independent predictor of
TVR (odds ratio 2.87, 95% confidence interval 1.13 to 7.24; p  0.03). Optimal glycemic
control was associated with a lower rate of cardiac rehospitalization (15% vs. 31%, p  0.03)
and recurrent angina (13% vs. 37%, p  0.002) at 12-month follow-up.
CONCLUSIONS In diabetic patients undergoing elective PCI, optimal glycemic control (A1c 7%) is
associated with a lower rate of TVR, cardiac rehospitalization, and recurrent angina. These
data suggest that aggressive treatment of DM to achieve A1c 7% is beneficial in improving
the clinical outcome after PCI. (J Am Coll Cardiol 2004;43:8–14) © 2004 by the American
College of Cardiology Foundation
There are 17 million patients with diabetes in the U.S.
and an estimated 125 million worldwide. By the year 2025,
this number is expected to reach over 300 million. In 1997,
the estimated cost for diabetes and its resultant complica-
tions was $98 billion, with $7.6 billion accounting for
cardiovascular complications alone (1). Current statistics
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estimate that of the more than 1.5 million revascularization
procedures performed worldwide each year, 25% are for
diabetic patients. These figures underscore the enormous
health care challenge that diabetic patients with coronary
artery disease (CAD) represent.
Diabetes is a potent risk factor for the development and
progression of CAD (2–4). With advances in coronary
revascularization by use of thrombolytic therapy, percutane-
ous modalities, and surgical intervention, morbidity and
mortality from CAD have been significantly reduced. How-
ever, despite contemporary therapy, cardiovascular disease
accounts for 75% of all hospital admissions and 80% of
deaths in diabetic patients (5,6).
The major long-term limitation of percutaneous coronary
revascularization is restenosis. Diabetes is a strong predictor
of restenosis after coronary intervention. Although the
introduction of stents has improved the outcome after
intervention in diabetic patients (7), these patients are still at
a greater risk for restenosis than nondiabetic patients (8,9).
Recent investigations have shown that this is because of
exaggerated tissue proliferation and intimal hyperplasia
(10,11). This phenomenon appears to be partly due to the
diabetic state, which promotes restenosis via intrinsic coag-
ulation and thrombotic abnormalities, endothelial dysfunc-
tion, cellular and matrix proliferation, and formation of
advanced glycation end products (12,13). Despite this in-
formation on the pathogenesis of restenosis in diabetic
patients, the importance of glycemic control in the devel-
opment of restenosis after coronary intervention has not
been extensively investigated.
In this study, we examined the association between
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glycemic control, as determined by hemoglobin A1c (A1c),
and the incidence of target vessel revascularization (TVR) in
diabetic patients undergoing elective percutaneous coronary
intervention (PCI).
METHODS
Study design. This investigation was approved by the
Human Investigation Committee at the William Beaumont
Hospital. From January 1998 to December 1999, diabetic
patients undergoing planned a percutaneous intervention of
de novo coronary artery lesions were identified and screened
for participation in this study. Diet-controlled or type I
diabetic patients, patients requiring urgent procedures for
unstable coronary syndromes, and patients undergoing in-
terventions in multiple vessels, previously instrumented
vessels, or vein grafts were excluded. A total of 179
consecutive eligible diabetic patients were prospectively
enrolled during this period. Sixty nondiabetic patients who
underwent elective PCI during the same period and who
met the aforementioned entry criteria were randomly se-
lected as the control group.
Before cardiac catheterization, baseline laboratory stud-
ies, including A1c, lipid panel, and fibrinogen, were drawn.
Coronary intervention was performed using standard tech-
niques and could include, but was not limited to, percuta-
neous transluminal coronary angioplasty (PTCA), intra-
coronary stenting, and mechanical rotational atherectomy.
All patients were treated with aspirin. After stent implan-
tation, all patients received either clopidogrel (75 mg/day
for four weeks) or ticlopidine (250 mg orally twice a day for
two to four weeks). Other adjunctive pharmacotherapy was
administered at the discretion of the operator.
Clinical follow-up was performed by telephone interview
and by review of the hospital record at 6 and 12 months
after the intervention. Repeat cardiac catheterization was
performed for recurrent symptoms or objective evidence of
ischemia with provocative testing. Routine angiographic
follow-up was not undertaken.
Angiographic analysis. The majority of patients had a
single lesion treated at the time of PCI. In patients with
multiple lesions treated, PCI was performed only on lesions
within the same vessel. Quantitative coronary angiography
was performed using an automated edge-detection system
(Quantcor, Siemens Medical Inc., Malvern, Pennsylvania)
by a single observer blinded to the clinical details and
outcomes. Calibration was based on the dimension of a
contrast-filled catheter. The following parameters were
measured in two orthogonal projections before and after
coronary intervention: lesion length, reference vessel diam-
eter, minimum luminal diameter (MLD), and percent
diameter stenosis. All lesions were classified in accordance
with the American Heart Association/American College of
Cardiology (AHA/ACC) classification scheme (14).
End points. The primary end point of the study was the
need for TVR (surgical or percutaneous) at 12 months.
Secondary end points included post-procedural cardiac
death, myocardial infarction (MI), recurrent angina, stroke,
congestive heart failure (CHF), renal failure, and cardiac
rehospitalization.
Definitions. Diabetic patients were identified as patients
undergoing treatment with insulin or oral hypoglycemic
medications. Diabetic patients were stratified into two
groups based on glycemic control. In accordance with the
American Diabetes Association guidelines (15), “optimal
glycemic control” was defined as A1c7%, and “suboptimal
control” was defined as A1c 7%. “Procedural success” was
defined as 50% residual diameter stenosis and Thrombol-
ysis in Myocardial Infarction flow grade 3 in the absence of
major in-hospital complications (death, MI, or urgent
coronary artery bypass graft surgery [CABG]). “Acute gain”
was defined as the difference between MLD before and after
coronary intervention. “Myocardial infarction” was defined
by the presence of new Q waves on the follow-up electro-
cardiogram or elevation of creatine kinase to greater than
three times normal. “Cardiovascular mortality” was defined
as death attributable to MI, CHF, or arrhythmia. “Target
vessel revascularization” was defined as the need for either
surgical or percutaneous revascularization of the initial
vessel intervened upon and excludes subsequent revascular-
ization of a newly diseased or previously diseased vessel(s).
Statistical analysis. Statistical analysis was performed us-
ing the Statistical Analysis Software package (SAS, version
8.2). Continuous variables are expressed as the mean  SD
and were analyzed for significant differences using one-way
analysis of variance, when being compared among all three
groups, or the two-tailed Student t test, when comparing
between diabetic and nondiabetic patients and between
diabetic patients with A1c 7% and those with A1c 7%.
Multiple comparisons were made; thus, adjustments using
the Bonferroni correction method were implemented. Cat-
egorical variables were analyzed for significant differences,
using Pearson’s chi-square test, two-tailed Fischer exact
test, or Cochran-Mantel-Haenszel test, as appropriate. In
the diabetic cohort, all baseline characteristics, laboratory
data, and angiographic parameters were analyzed to deter-
mine the independent predictors of TVR. All variables with
a p value 0.2 were entered into a forward stepwise
multiple logistic regression analysis to determine the most
parsimonious subset of variables that best explained the
occurrence of TVR among diabetic patients. Similar anal-
Abbreviations and Acronyms
A1c  hemoglobin A1c
CABG coronary artery bypass graft surgery
CAD  coronary artery disease
CHF  congestive heart failure
MI  myocardial infarction
MLD  minimum luminal diameter
PCI  percutaneous coronary intervention
PTCA  percutaneous transluminal coronary angioplasty
TVR  target vessel revascularization
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yses were performed to determine independent predictors of
cardiac rehospitalization and recurrent angina. A p value
0.05 was considered statistically significant unless the
Bonferroni correction method for multiple comparisons was
utilized, in which case a p value 0.025 was considered
statistically significant.
RESULTS
Demographics. DIABETIC PATIENTS VERSUS NONDIA-
BETIC PATIENTS. Diabetic patients were less likely to be
male and had a higher prevalence of hypertension (75% vs.
58%). Compared with nondiabetic patients, diabetic pa-
tients had a higher body mass index (mean 32 vs. 29 kg/m2)
and higher levels of fibrinogen (324 vs. 295 mg/dl), triglyc-
erides (159 vs. 132 mg/dl), blood urea nitrogen (20 vs. 16
mg/dl), and creatinine (1.2 vs. 1.0 mg/dl) (Tables 1 and 2).
Intracoronary stenting was performed in 67% of diabetic
patients and 69% of nondiabetic patients (p  0.82). The
lesion location, AHA/ACC lesion classification, angio-
graphic measurements, and frequency of multi-lesion PCI
were similar between patients with and without diabetes
(Table 3).
DIABETIC PATIENTS WITH OPTIMAL VERSUS SUBOPTIMAL
GLYCEMIC CONTROL. Diabetic patients with suboptimal
glycemic control (A1c 7%) were more often treated with
insulin (54% vs. 27%) and less often male (59% vs. 75%).
Compared with diabetic patients with A1c7%, those with
A1c 7% had similar risk factors, historical profile, and
Table 1. Clinical Characteristics in Diabetic and Nondiabetic Patients
Non-DM
(n  60)
DM Comparisons (p Value)
A1c <7%
(n  52)
A1c >7%
(n  127)
Across
Groups*
Non-DM
vs. DM† DM‡
Oral hypoglycemic medications — 38 (73%) 59 (46%) — — 0.002
Insulin treatment — 14 (27%) 68 (54%) — — —
Age (yrs) 63  11 65  11 63  11 0.69§ 0.60 0.51§
Males 47 (78%) 39 (75%) 75 (59%) 0.01 0.04 0.04
Risk factors
Current smoker 8 (13%) 9 (17%) 13 (10%) 0.42 0.83 0.19
Hypertension 35 (58%) 35 (67%) 99 (78%) 0.02 0.01 0.14
Hyperlipidemia 36 (60%) 35 (67%) 84 (66%) 0.65 0.36 0.88
Body mass index (kg/m2) 29  4.4 32  20 32  6.4 0.20§ 0.008 0.96
History
MI 24 (40%) 18 (35%) 34 (27%) 0.20 0.13 0.32
PTCA 24 (40%) 23 (44%) 53 (42%) 0.90 0.74 0.76
CABG 13 (22%) 17 (33%) 30 (24%) 0.35 0.48 0.21
CHF 6 (10%) 10 (19%) 19 (15%) 0.38 0.24 0.48
Arrhythmia 3 (5%) 4 (8%) 6 (5%) 0.72 1.00 0.48
Renal failure 2 (3%) 7 (13%) 10 (8%) 0.14 0.17 0.27
*Pearson’s chi-square test (or two-tailed Fisher exact test if 5 events), unless otherwise indicated. †Difference between nondiabetic patients and all diabetic patients (A1c 7%
and A1c 7%), using Pearson’s chi-square test (or two-tailed Fisher exact test if 5 events), unless otherwise indicated. ‡Difference between diabetic patients with A1c 7%
and diabetic patients with A1c 7%, using Pearson’s chi-square test (or two-tailed Fischer exact test), unless otherwise indicated. §Difference among all groups using one-way
analysis of variance with contrasts. Contrasts were adjusted using the Bonferroni correction method for multiple comparisons. Difference between groups using the two-tailed
Student t test. Data are presented as the mean value  SD or number (%) of subjects.
A1c  hemoglobin A1c; CABG  coronary artery bypass grafting; CHF  congestive heart failure; DM  diabetic patients; non-DM  nondiabetic patients; MI 
myocardial infarction; PTCA  percutaneous transluminal coronary angioplasty.
Table 2. Laboratory Data for Diabetic and Nondiabetic Patients
Non-DM
(n  60)
DM Comparisons (p Value)
A1c <7%
(n  52)
A1c >7%
(n  127)
Across
Groups*
Non-DM
vs. DM† DM‡
A1c (%) 6.1  0.8 6.5  0.5 8.8  1.6 — 0.001 —
Fibrinogen (mg/dl) 295  76 311  93 328  94 0.08 0.19 0.69
Cholesterol (mg/dl) 176  42 177  35 176  58 0.99 1.0 1.0
HDL (mg/dl) 42  11 39  12 40  11 0.26 0.27 0.65
LDL (mg/dl) 108  31 106  31 107  65 0.98 1.0 1.0
Total/HDL cholesterol ratio 4.4  1.1 5.0  2.2 4.6  1.7 0.16 0.26 0.30
Triglycerides (mg/dl) 132  77 162  97 158  104 0.19 0.14 1.0
BUN (mg/dl) 16  5.5 22  12 20  9.8 0.001 0.001 0.28
Creatinine (mg/dl) 1.0  0.2 1.4  1.0 1.1  0.9 0.10 0.018 0.19
*Difference among groups using one-way analysis of variance with contrasts. Contrasts were adjusted using the Bonferroni correction method for multiple comparisons.
†Difference between nondiabetic patients and all diabetic patients (A1c 7% and 7%), using the two-tailed Student t test. ‡Contrast between diabetic patients with A1c 7%
and diabetic patients with A1c 7%. Comparisons were adjusted using the Bonferroni correction method for multiple comparisons. Data are presented as the mean value  SD.
BUN  blood urea nitrogen; HDL  high-density lipoprotein; LDL  low-density lipoprotein; other abbreviations as in Table 1.
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laboratory values (Tables 1 and 2). Angiographic analysis
revealed no significant differences in lesion length, reference
vessel diameter, MLD, diameter stenosis, or acute gain
between diabetic patients with optimal versus suboptimal
glycemic control (Table 3).
Target vessel revascularization. The incidence of TVR at
12 months was determined according to diabetic status and
glycemic control. Well-controlled diabetic patients had a
rate of TVR similar to that of nondiabetic patients (15% vs.
18%, p  0.68). Among diabetic patients, those with A1c
7% had a significantly lower rate of TVR than those with
A1c 7% (15% vs. 34%, p  0.02) (Fig. 1). Multivariate
analysis disclosed that A1c 7% was a significant indepen-
dent predictor of TVR 12 months following PCI (odds ratio
[OR] 2.87, 95% confidence interval [CI] 1.13 to 7.24; p 
0.03).
Insulin-requiring diabetic patients had a significantly
higher rate of TVR than nondiabetic patients (35% vs. 18%;
OR 2.44, 95% CI 1.10 to 5.40; p  0.03). Among diabetic
patients, there was a trend toward a higher TVR rate in
those treated with insulin compared to those treated with
oral hypoglycemics (35% vs. 23%, p  0.06) (Fig. 2). On
multivariate analysis, insulin therapy was of borderline
Table 3. Angiographic Data
Non-DM
DM Comparisons (p Value)
A1c <7% A1c >7% Across Groups* Non-DM vs. DM† DM‡
Number of lesions 67 53 137
Multilesion PCI 4 (6.7%) 1 (2.0%) 7 (5.5%) 0.48§ 0.50§ 0.29§
Lesion location 0.54§
LMCA 0 (0%) 1 (2%) 3 (2%) 0.48§ 0.89§
LAD 23 (34%) 18 (34%) 46 (33%) 0.99§ 0.96§
LCx 29 (43%) 14 (26%) 40 (29%) 0.08§ 0.70§
RCA 15 (22%) 20 (38%) 48 (35%) 0.12§ 0.73§
Lesion type 0.36
A 8 (12%) 7 (13%) 16 (11%) 0.96§ 0.77§
B 46 (69%) 30 (56%) 5 (55%) 0.16§ 0.82§
C 13 (19%) 16 (30%) 46 (34%) 0.11§ 0.66§
QCA data
Length (mm) 12  6.5 13  5.9 14  7.9 0.17 0.71 0.31
Pre-intervention
RVD (mm) 2.8  0.6 2.7  0.5 2.8  0.7 0.53 1.0 0.52
MLD (mm) 0.6  0.4 0.7  0.4 0.7  0.4 0.75 0.97 1.0
DS (%) 78  14 77  13 77  13 0.82 1.0 1.0
Post-intervention
RVD (mm) 2.8  0.6 2.7  0.5 2.8  0.7 0.53 1.0 0.55
MLD (mm) 2.6  0.7 2.5  0.6 2.6  0.7 0.46 0.77 0.56
DS (%) 9.9  10 10  11 11  12 0.91 1.0 1.0
Short-term gain (mm) 2.0  0.7 1.8  0.6 2.0  0.9 0.56 1.0 0.60
*Difference among groups using one-way analysis of variance with contrasts, unless otherwise indicated. †Difference between nondiabetic patients and all diabetic patients, (A1c
7% and A1c 7%), using the two-tailed Student t test, unless otherwise indicated. ‡Contrasts between diabetic patients with A1c 7% and diabetic patients with A1c 7%.
Comparisons were adjusted using the Bonferroni correction method for multiple comparisons, unless otherwise indicated. §Pearson’s chi-square test or two-tailed Fisher exact
test if 5 events. Difference among all groups using the Cochran-Mantel-Haenszel test. Data are presented as the mean  SD or number (%) of lesions.
DS  diameter stenosis; LAD  left anterior descending coronary artery; LCx  left circumflex coronary artery; LMCA  left main coronary artery; MLD  minimal
luminar diameter; PCI percutaneous coronary intervention; QCA quantitative coronary angiography; RCA right coronary artery; RVD reference vessel diameter; other
abbreviations as in Table 1.
Figure 1. Incidence of target vessel revascularization in diabetic and
nondiabetic patients. A1c  hemoglobin A1c.
Figure 2. Incidence of target vessel revascularization according to treat-
ment regimen.
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significance as an independent correlate of 12-month TVR
(OR 1.96, 95% CI 0.94 to 4.10; p  0.07).
The subgroup of patients undergoing intracoronary stent
implantation was analyzed separately. In the stent popula-
tion, well-controlled diabetic patients had a rate of TVR
similar to that of patients without diabetes (16% vs. 13%, p
 0.68). Among diabetic patients undergoing stent place-
ment, those with A1c 7% had a higher rate of TVR than
those with A1c 7% (33% vs. 16%, p  0.05).
Follow-up events. Analysis of follow-up data revealed no
significant differences in the rate of cardiovascular mortality,
MI, subsequent CABG, recurrent angina, CHF, arrhyth-
mias, stroke, renal failure, or cardiac rehospitalization in
patients with diabetes compared with patients without
diabetes. However, suboptimally controlled diabetic pa-
tients had a higher incidence of recurrent angina (37% vs.
13%, p  0.002) and cardiac rehospitalization (31% vs.
15%, p  0.03) than well-controlled diabetic patients
(Table 4). Multivariate analysis disclosed that A1c7% was
a significant independent predictor of both cardiac rehospi-
talization (OR 2.44, 95% CI 1.05 to 5.66; p  0.04) and
recurrent angina (OR 4.03, 95% CI 1.66 to 9.78; p 
0.002).
DISCUSSION
Diabetes is associated with a two- to four-fold increase in
the risk of developing cardiovascular disease and is a
well-recognized risk factor for adverse outcomes after cor-
onary intervention (3,5,9,16). Despite these data, little
information exists regarding the effect of glycemic control
on outcome in this high-risk patient population. This is one
of the first studies to prospectively evaluate the impact of
glycemic control on outcome in diabetic patients undergo-
ing PCI. Our findings demonstrate that despite similar
baseline clinical and angiographic characteristics, diabetic
patients with A1c 7% at the time of PCI had a signifi-
cantly lower rate of TVR than did those with A1c 7%.
Furthermore, optimally controlled diabetic patients had
rates of TVR similar to those of nondiabetic patients. These
observations demonstrate the importance of glycemic con-
trol in reducing restenosis after coronary intervention.
Glycemic control and events after PCI. Findings from
the United Kingdom Prospective Diabetes Study (UKPDS)
Group (17) showed that intensive glycemic control in
patients with type II diabetes resulted in a significant
improvement in microvascular events. Despite this, the
effect of tight glycemic control on macrovascular end points
remained unclear, as only a trend toward improvement in
fatal MI, nonfatal MI, and sudden death was observed (16%
risk reduction, p  0.052). Recently, however, a growing
body of evidence has shown an association between optimal
glycemic control and improvement in macrovascular events.
Khaw et al. (18) demonstrated a significant increase in
all-cause, cardiac, and ischemic mortality with increasing
levels of A1c. In their study, a 1% increase in A1c was
associated with a 38% increase in cardiovascular mortality
and a 44% increase in risk of ischemic mortality in diabetic
patients. In the present study, although the rate of cardiac
rehospitalization after PCI was higher in diabetic patients
with A1c 7% than in those with A1c 7%, an increase in
cardiovascular mortality was not observed. There are several
potential explanations regarding these discordant findings.
The small sample size and short duration of the study
limited the ability of this investigation to detect a difference
in mortality. Furthermore, diabetic patients often have
multiple co-existing cardiovascular risk factors; therefore,
the therapeutic efficacy of treatments aimed at reducing
overall cardiovascular risk (e.g., lipid-lowering and anti-
platelet therapies) must be considered. Nevertheless, al-
though an increase in cardiovascular mortality in poorly
controlled diabetics was not observed, these data do indicate
that glycemic control may play an important role in the
pathophysiology of the restenotic process.
In a small series of diabetic patients undergoing PTCA,
Asakura et al. (19) found a significantly higher rate of
restenosis in poorly controlled diabetic patients compared
with moderately or well-controlled diabetic patients. Mul-
tivariate analysis disclosed a significant correlation between
Table 4. Follow-Up Data
Non-DM
DM Comparisons (p Value)
A1c <7% A1c >7% Across Groups* Non-DM vs. DM† DM‡
Cardiovascular mortality 3 (5%) 3 (6%) 2 (2%) 0.24 0.72 0.12
MI 2 (3%) 3 (6%) 7 (5%) 0.87 0.74 0.72
CABG 1 (2%) 2 (4%) 8 (6%) 0.35 0.30 0.73
Recurrent angina 14 (23%) 7 (13%) 47 (37%) 0.004 0.31 0.002
CHF 1 (2%) 1 (2%) 7 (6%) 0.32 0.46 0.44
Arrhythmia 1 (2%) 1 (2%) 2 (1%) 0.99 1.00 1.00
CVA 0 (0%) 1 (2%) 2 (1%) 0.50 0.58 1.00
Renal failure 1 (2%) 1 (2%) 2 (2%) 0.99 1.00 1.00
Cardiac rehospitalization 12 (20%) 8 (15%) 39 (31%) 0.06 0.33 0.03
Noncardiac rehospitalization 5 (8%) 4 (8%) 13 (10%) 0.84 0.79 0.60
*Pearson’s chi-square test (or Fisher exact test if 5 events). †Difference between nondiabetic patients and all diabetic patients (A1c 7% and A1c 7%), using Pearson’s
chi-square test (or Fisher exact test if 5 events). ‡Difference between diabetic patients with A1c 7% and diabetic patients with A1c 7%, using Pearson’s chi-square test (or
Fisher exact test if 5 events). Data are presented as the number (%) of subjects.
Abbreviations as in Table 1.
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restenosis and the degree of glycemic control. These find-
ings are contrary to those of Hasdai et al. (20), who found
no significant relationship between the degree of glycemia,
as measured by glycated hemoglobin, and outcome after
PCI. These discordant observations may be due to the
retrospective nature of the study and potential for significant
sampling error, as only 64% of diabetic patients in this study
had glycated hemoglobin drawn within 100 days of the
index procedure.
This study demonstrates that after vascular injury induced
by catheter-based intervention, the rate of TVR is signifi-
cantly reduced in patients with tight glycemic control.
These findings are supported by the fact that chronic
hyperglycemia is known to induce vascular endothelial cell
damage, with resultant vasomotor dysfunction, excessive
extracellular matrix formation, and increased cellular prolif-
eration. Furthermore, increased accumulation of advanced
glycation end products in the vessel wall leads to decreased
vascular compliance, enhanced smooth muscle proliferation,
and augmentation of the inflammatory response after vas-
cular damage from coronary interventions. Many of these
abnormalities may be reversible with improved glycemic
control (12,13). Our findings imply that strict glycometa-
bolic control may be instrumental in preventing the unto-
ward pathophysiologic mechanisms by which hyperglycemia
leads to accelerated restenosis in diabetic patients.
Hyperinsulinemia and restenosis. Hyperinsulinemia has
been implicated in a variety of mechanisms that may
predispose diabetic patients to increased rates of restenosis
after PCI. Insulin may induce endothelial dysfunction,
increase smooth muscle cell proliferation, promote extracel-
lular matrix deposition, alter lipid metabolism, and increase
plasminogen activator inhibitor-1 levels, resulting in unto-
ward imbalances in the fibrinolytic system (12,13). These
findings have led some to theorize that hyperinsulinemia
(whether from exogenous therapy or insulin resistance
states) could be a major contributing factor in the progres-
sion of coronary disease after vascular injury induced by PCI
(21). Furthermore, concerns have been raised over the
management of diabetes with insulin therapy, as exog-
enously administered insulin may potentiate progression of
CAD via these atherogenic mechanisms (22,23). Clinical
data regarding the impact of insulin therapy on restenosis
after PCI have been inconclusive. Abizaid et al. (9) found an
increased rate of target lesion revascularization in insulin-
treated diabetic patients compared with nondiabetic pa-
tients. However, there was no difference in target lesion
revascularization between non–insulin-treated diabetic pa-
tients and nondiabetic patients, implying that insulin treat-
ment may predict an unfavorable clinical outcome in dia-
betic patients undergoing percutaneous revascularization.
Conversely, Schofer et al. (24) demonstrated no significant
difference in restenosis rates between insulin-treated and
non–insulin-treated diabetic patients.
In this study, we found that compared with patients
without diabetes, both insulin-treated and orally treated
diabetic patients had significantly higher rates of clinical
restenosis. When the effect of the treatment regimen was
examined, there was a trend toward a higher rate of TVR in
insulin-treated patients compared with orally treated pa-
tients. In a multiple logistic regression analysis, although
A1c 7% was shown to be a significant independent
predictor of TVR, the use of insulin achieved borderline
significance as a correlate of the need for revascularization.
Although the use of insulin did not reach statistical signif-
icance, perhaps due to the limited sample size, our results
suggest that in addition to hyperglycemia, insulin therapy
may also be an important potentiating factor in the rest-
enotic process. Given these data, the role of insulin-
sensitizing medications, such as metformin and the thiazo-
lidinediones, either alone or in combination therapy, must
be prospectively investigated to determine whether such
therapies can reduce events after PCI.
Study limitations. This study reports a single-center expe-
rience with a relatively small number of patients. Routine
angiographic follow-up was not performed, and thus abso-
lute restenosis rates could not be reported. Despite this, we
were able to obtain complete clinical follow-up data on all
patients enrolled in the study and were thus able to
accurately assess rates of cardiovascular mortality, MI, and
TVR, which are perhaps more clinically relevant end points.
The definition of TVR used in this study is limited solely to
the initial vessel intervened upon and, as such, gives no
information on the progression of disease in other vessels or
the need for revascularization in previously diseased vessels.
The effect of other metabolic parameters, such as insulin
levels, C-peptide levels, and inflammatory markers, on TVR
was not examined in this study and merits further
investigation.
Conclusions. In this study, we found a significantly higher
rate of ischemia-driven TVR, cardiac rehospitalization, and
recurrent angina in diabetic patients with suboptimal gly-
cemic control. Furthermore, well-controlled diabetic pa-
tients had rates of adverse clinical events comparable to
those of nondiabetic patients. These data suggest that
aggressive treatment of diabetes to achieve A1c levels 7%
may be beneficial in reducing the risk of restenosis and may
improve the clinical outcome after PCI.
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